Regorafenib: a novel drug for metastatic colorectal cancer treatment
https://doi.org/10.18027/2224-5057-2016-2-72-80
Abstract
Metastatic colorectal cancer is a serious medical and social problem. Development of new treatment approaches, drugs, especially targeted drugs, leads to the instantly increasing of survival in this disease. Regorafenib is recently approved for use in advanced metastatic colorectal cancer. This drug significantly improves treatment results with acceptable safety profile. In this review results of large controlled studies of regorafenib in colorectal cancer are discussed. Data on overall survival, progression-free survival, objective response rate and safety profile are consecutively evaluated.
About the Author
Marina Igorevna Sekacheva
Petrovsky National Research Centre of Surgery
Russian Federation
Russian Federation
MD, PhD, DSc, oncologist, academic secretary
References
1. http://globocan.iarc.fr/old/bar_pop.asp?selection=163643&title=Russian+Federation&sex=0&statistic=0&window=1&grid=1&color1=5&color1e=&color2=4&color2e=&orientation=1&submit =%C2%A0Execute
2. Wilhelm S. M., Dumas J., Adnane L., et al. Regorafenib (BAY73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255.
3. Schmieder R., Hoffmann J., Becker M., et al. Regorafenib (BAY73–4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014;135:1487–1496.
4. Strumberg D., Scheulen M. E., Schultheis B., et al. Regorafenib (BAY73–4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–1727).
5. Solimando Jr. D.A., Waddell J. A. Drug monographs: bosutinib and regorafenib. Hosp Pharm. 2013;48:190–194.
6. Zopf D., Heinig R., Thierauch K-H., et al. Abstract 1666: Regorafenib (BAY73–4506): preclinical pharmacology and clinical identification and quantification of its major metabolites. Cancer Res. 2010;70 (8 Supplement):1666.
7. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;38:303–312.
8. Ricotta R., Sartore-Bianchi A., Verrioli A., Vanzulli A., Siena S. Regorafenib for metastatic colorectal cancer. Lancet. 2013;381(9877):1537.
9. Li J., Qin S., Xu R. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–629.
10. Tougeron D., Desseigne F., Etienne P. L., Dourthe L. M., Mineur L., Paule B. et al. REBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC). Ann Oncol. 2014;25(4): iv167–209.
11. Van Cutsem E., Ciardiello F., Seitz J-F. et al. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol. 2015;26(4 Supplement): iv118.
Review
For citations:
Sekacheva M.I. Regorafenib: a novel drug for metastatic colorectal cancer treatment. Malignant tumours. 2016;(2):72-80. (In Russ.) https://doi.org/10.18027/2224-5057-2016-2-72-80
Views:
2027
Email this article 